Angelika Bongers
Sydney, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
BCL-2 and MCL1 co-inhibition enhances glucocorticoid therapy in preclinical models of infant KMT2A-rearranged acute lymphoblastic leukaemia.
Journal: British journal of haematology
Published: October 26, 2025
Polyamine depletion limits progression of acute leukaemia.
Journal: International journal of cancer
Published: July 23, 2024
FDA-approved disulfiram as a novel treatment for aggressive leukemia.
Journal: Journal of molecular medicine (Berlin, Germany)
Published: May 26, 2023
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
Journal: Frontiers in oncology
Published: January 27, 2022
Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia.
Journal: Frontiers in oncology
Published: September 20, 2021
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 30, 2020
Exploiting the reactive oxygen species imbalance in high-risk paediatric acute lymphoblastic leukaemia through auranofin.
Journal: British journal of cancer
Published: January 29, 2020
ABCC4/MRP4 contributes to the aggressiveness of Myc-associated epithelial ovarian cancer.
Journal: International journal of cancer
Published: January 12, 2020
Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Journal: International journal of cancer
Published: February 27, 2019
Last Updated: 09/26/2026